
Musings on the latest developments in AIDS vaccine research from the IAVI Report team. |
|
| Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XsnLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | FileType | xsn | 255 | | Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | ProgId | InfoPath.Document | 255 | | Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | ProgId | InfoPath.Document.2 | 255 | | Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | ProgId | InfoPath.Document.3 | 255 | | Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | ProgId | InfoPath.Document.4 | 255 | | View in Web Browser | /_layouts/images/ichtmxls.gif | /IRblog/_layouts/xlviewer.aspx?listguid={ListId}&itemid={ItemId}&DefaultItemOpen=1 | 0x0 | 0x1 | FileType | xlsx | 255 | | View in Web Browser | /_layouts/images/ichtmxls.gif | /IRblog/_layouts/xlviewer.aspx?listguid={ListId}&itemid={ItemId}&DefaultItemOpen=1 | 0x0 | 0x1 | FileType | xlsb | 255 | | Snapshot in Excel | /_layouts/images/ewr134.gif | /IRblog/_layouts/xlviewer.aspx?listguid={ListId}&itemid={ItemId}&Snapshot=1 | 0x0 | 0x1 | FileType | xlsx | 256 | | Snapshot in Excel | /_layouts/images/ewr134.gif | /IRblog/_layouts/xlviewer.aspx?listguid={ListId}&itemid={ItemId}&Snapshot=1 | 0x0 | 0x1 | FileType | xlsb | 256 |
|
|
|
|
|
|
|
IAVIReport.org > Blog
|
|
|
December 02, 2011 03:38 PMThe latest issue of VAX is online now. Read about the recent Phase III results of the malaria vaccine candidate RTS,S or learn more about the use of hormonal contraception and HIV infection risk in women.
November 11, 2011 11:27 PM
The underperformance of orally administered enteric vaccines in developing countries was the main topic of discussion today, the last day of the conference. In principle, this underperformance can be addressed by delivering vaccines through different routes. However, conventional intramuscular or subcutaneous immunizations often only induce weak immune responses in the gut where the infection occurs, and therefore protect only weakly against enteropathogens on the mucosal surface.
But yesterday, Swantje Hammerschmidt of Medical School Hannover reported evidence that the problem can be addressed by adding the vitamin A derivative retinoic acid (RA). November 10, 2011 12:41 PM
One question that keeps coming up at the meeting here is the paradox that compared with developed countries, some oral vaccines are less efficient in malnourished children in developing countries, even though such children show an overstimulation of their immune system in the gut.
A possible explanation was mentioned today by Per Brandtzaeg of the University of Oslo who gave an overview of the human intestinal immune system. He said that malnourished children in developing countries may have too many regulatory T cells (or Tregs), which may explain why their immune response to oral vaccines is suppressed. November 10, 2011 10:06 AM
All of the licensed influenza vaccines and most of the candidates in clinical or pre-clinical development target the hemagluttinen (HA) antigen on the surface of the virus. This is partly because induction of antibodies against HA is a correlate of immune-mediated protection against influenza, making the surface protein a logical target for the production and quality assessment of vaccines. November 09, 2011 02:27 PM
Bacterial infections of the gut are one reason children in the developing world are malnourished, and malnourishment can lead to a poorer response to oral vaccines. One way to protect from the effects of such infections is to add probiotic bacteria to food, but scientists are just beginning to learn how such bacteria actually protect. Today, Shinji Fukuda from the RIKEN Institute in Yokohama, Japan, reported that he and his colleagues showed how a certain type of probiotic bacteria called Bifidobacterium that can be found in yoghurt can protect mice from dying from an otherwise lethal Escherichia coli (E. coli) infection (Nature 469, 543, 2011). November 09, 2011 01:25 PM
For the past 50 years, vaccine manufacturers in the United States have used egg-based technology to develop the seasonal influenza vaccine, and they might have stuck to this method were it not for the emergence of the H5N1 virus in Asia. Since its appearance in the mid-1990s, the highly pathogenic strain of influenza, which jumped directly from birds to humans, has resulted in 500 cases and 300 deaths. November 08, 2011 02:10 PM
In today’s morning session, it was interesting to hear that compared with children in developed countries, children in the developing world show a poorer response to oral vaccines (such as polio vaccine) whereas their response to vaccines that are administered systemically by injection (such as measles vaccine) doesn’t appear to be much different.
William Petri from the University of Virginia reported on studies of the possible reasons for why these children respond so poorly to oral vaccination. November 07, 2011 02:15 PM
A healthy gut and good nutrition are important for a healthy immune system and a good immune response to vaccination, so it's not surprising that vaccines have been found to be less efficient in malnourished children. Still, “surprisingly little” is known about the impact nutrition has on the mucosal immune system of the digestive tract, according to the organizers of the Keystone Symposium on Malnutrition, Gut-Microbial Interactions and Mucosal Immunity to Vaccines, which is taking place in New Delhi Nov. 7-11. The meeting focuses on the role nutrition plays for gut immunity, knowledge of which could lead to the development of better vaccines in malnourished children. October 27, 2011 10:00 PM
Thomas Hope of Northwestern University started today’s meeting with a talk about his studies of how fluorescently labeled HIV particles enter the mucosal barrier of the macaque reproductive tract. One important topic is to study if and how the menstrual cycle affects this process, Hope said. “[This is] becoming an interesting and important topic that many groups need to consider in prevention science and pathogenesis and transmission,” he said.
Hope studied viral entry into the vagina of macaques that had been treated with Depo-Provera, a contraceptive that mimicks the luteal phase of the menstrual cycle by thinning the vaginal mucosa and has recently been shown to double the susceptibility to HIV infection in women (Lancet Infect. Dis. 2011; doi:10.1016/S1473-3099(11)70247-X). He found that in Depo-Provera treated animals, more T cells came close to the surface, possibly explaining why Depo-Provera increases transmission. October 26, 2011 10:09 PM
This year’s 29th Annual Symposium on Nonhuman Primate (NHP) Models for AIDS, which takes place from October 25-28 in Seattle, has about 50% more registrants than last year, and the number of international registrants has doubled, said David Anderson, conference chair and director of the Washington National Primate Research Center. It could be the beautiful location, but Anderson said part of the reason is that NHP research is becoming more collaborative. “I think part of why we have an increase in attendance this year is because science is getting bigger, more complex and getting characterized by partnerships,” he said, adding that one example is systems biology which involves “pulling people from a lot of different areas together.”
Another example of how the field is currently moving towards large scale projects is the NHP reference transcriptome project, which aims to sequence the transcriptomes (the totality of all expressed RNAs) of no less than 20 tissues from 15 NHP species. 1
- 10  |
|
|
|
|
|
|